← Leaderboards
Jeffrey W Smith
Burnham Institute For Medical Research
$49,666,414
Attributed
$50,799,337
Total exposure
34
Grants
23
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $10.7M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$69,883,029 · 35
By mechanism
U54$27,091,277 · 14
R01$17,113,186 · 9
U01$12,761,877 · 1
P01$9,964,126 · 5
P30$1,301,903 · 2
S10$859,462 · 2
Top collaborators
- Nicholas David Cosford3 shared
Most similar at Burnham Institute For Medical Research
Same institution · by research overlap
- Steven J Kridel$4,340,375
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseMalignant NeoplasmsProteinsCellsTumorMouse ModelInhibitor/AntagonistFundingMedicalLinkSmall MoleculeDiagnosisProgramsIn VivoDesignPathway InteractionsIntegrinsMass SpectrometryLeadEnzymesPharmaceutical PreparationsResearch PersonnelInstitutesAngiogenesis
Grant awards (102)
CORE D - Proteomics Core$589,543
P01 · FY2025 · HL · contact PI
CORE D - Proteomics Core$581,860
P01 · FY2024 · HL · contact PI
CORE D - Proteomics Core$589,497
P01 · FY2023 · HL · contact PI
CORE D - Proteomics Core$589,485
P01 · FY2022 · HL · contact PI
CORE D - Proteomics Core$607,619
P01 · FY2021 · HL · contact PI
Core D: Proteomics Core Facility$366,735
P01 · FY2020 · HL · contact PI
Project 3: MITF in Drug Resistance and Metabolism in Melanoma$329,332
P01 · FY2020 · CA · contact PI
De-orphanizing MMPs in intercelluar interactions$522,356
R01 · FY2019 · GM · contact PI
Core D: Proteomics Core Facility$366,735
P01 · FY2019 · HL · contact PI
Project 3: MITF in Drug Resistance and Metabolism in Melanoma$319,453
P01 · FY2019 · CA · contact PI
De-orphanizing MMPs in intercelluar interactions$522,356
R01 · FY2018 · GM · contact PI
Core D: Proteomics Core Facility$366,735
P01 · FY2018 · HL · contact PI
Project 3: MITF in Drug Resistance and Metabolism in Melanoma$329,332
P01 · FY2018 · CA · contact PI
De-orphanizing MMPs in intercelluar interactions$522,356
R01 · FY2017 · GM · contact PI
Core D: Proteomics Core Facility$366,727
P01 · FY2017 · HL · contact PI
Project 3: MITF in Drug Resistance and Metabolism in Melanoma$177,178
P01 · FY2017 · CA · contact PI
Lead Optimization of Novel Inhibitors of the Thioesterase Domain of FASN$755,282
R01 · FY2016 · CA
De-orphanizing MMPs in intercelluar interactions$522,356
R01 · FY2016 · GM · contact PI
Project 3: MITF in Drug Resistance and Metabolism in Melanoma$428,781
P01 · FY2016 · CA · contact PI
Core D: Proteomics Core Facility$379,500
P01 · FY2016 · HL · contact PI
Lead Optimization of Novel Inhibitors of the Thioesterase Domain of FASN$755,282
R01 · FY2015 · CA
Systems biology of glutamine utilization in melanoma$212,063
R21 · FY2015 · CA · contact PI
Lead Optimization of Novel Inhibitors of the Thioesterase Domain of FASN$755,282
R01 · FY2014 · CA
Drug Discovery for Fatty Acid Synthase in Oncology$511,937
R01 · FY2014 · CA · contact PI
Systems biology of glutamine utilization in melanoma$254,475
R21 · FY2014 · CA · contact PI
Drug Discovery for Fatty Acid Synthase in Oncology$483,337
R01 · FY2013 · CA · contact PI
FXR signaling pathway is a valid target for chemoprevention in colorectal cancer$421,152
R01 · FY2013 · CA · contact PI
Drug Discovery for Fatty Acid Synthase in Oncology$503,641
R01 · FY2012 · CA · contact PI
FXR signaling pathway is a valid target for chemoprevention in colorectal cancer$451,786
R01 · FY2012 · CA · contact PI
Drug Discovery for Fatty Acid Synthase in Oncology$505,254
R01 · FY2011 · CA · contact PI
FXR signaling pathway is a valid target for chemoprevention in colorectal cancer$484,004
R01 · FY2011 · CA · contact PI
FXR signaling pathway is a valid target for chemoprevention in colorectal cancer$541,976
R01 · FY2010 · CA · contact PI
Drug Discovery for Fatty Acid Synthase in Oncology$521,711
R01 · FY2010 · CA · contact PI
Nanotherapy for Vulnerable Plaque$2,920,667
U01 · FY2009 · HL · contact PI
FXR signaling pathway is a valid target for chemoprevention in colorectal cancer$571,328
R01 · FY2009 · CA · contact PI
Metalloproteinases in Tumor Progression and Metastasis$516,592
R01 · FY2009 · CA · contact PI
CENTER ON PROTEOLYTIC PATHWAYS(RMI)$337,243
U54 · FY2009 · RR · contact PI
Center on Proteolytic Pathways(RMI)$337,243
U54 · FY2009 · RR · contact PI
Center on Proteolytic Pathways(RMI)$3,563,480
U54 · FY2008 · RR · contact PI
Nanotherapy for Vulnerable Plaque$2,846,417
U01 · FY2008 · HL · contact PI
CORE 6 : PROJECT LEADERSHIP AND ADMINISTRATION$1,529,174
U54 · FY2008 · RR · contact PI
Core--Drug Screening and Chemistry Facility$691,222
P01 · FY2008 · AI · contact PI
Metalloproteinases in Tumor Progression and Metastasis$501,543
R01 · FY2008 · CA · contact PI
CORE--Shared Resources Chemical Library$459,390
P30 · FY2008 · CA · contact PI
CORE 1 TRP2: PROTEASE ACTIVITY IMAGING TECHNOLOGY (PAIT)$352,373
U54 · FY2008 · RR · contact PI
Center on Proteolytic Pathways(RMI)$269,998
U54 · FY2008 · RR · contact PI
CORE 2 DB2: PROTEOLYTIC REGULATION OF HIF-1ALPHA$76,018
U54 · FY2008 · RR · contact PI
Center on Proteolytic Pathways(RMI)$3,530,653
U54 · FY2007 · RR · contact PI
Nanotherapy for Vulnerable Plaque$2,726,449
U01 · FY2007 · HL · contact PI
CORE 6 : PROJECT LEADERSHIP AND ADMINISTRATION$1,465,574
U54 · FY2007 · RR · contact PI
Core--Drug Screening and Chemistry Facility$685,306
P01 · FY2007 · AI · contact PI
Metalloproteinases in Tumor Progression and Metastasis$496,579
R01 · FY2007 · CA · contact PI
Vascular Integrins and Nitric Oxide$455,126
R01 · FY2007 · HL · contact PI
CORE--Shared Resources Chemical Library$426,278
P30 · FY2007 · CA · contact PI
CORE 1 TRP2: PROTEASE ACTIVITY IMAGING TECHNOLOGY (PAIT)$337,707
U54 · FY2007 · RR · contact PI
Center on Proteolytic Pathways(RMI)$143,250
U54 · FY2007 · RR · contact PI
Nanotherapy for Vulnerable Plaque$86,160
U01 · FY2007 · HL · contact PI
CORE 2 DB2: PROTEOLYTIC REGULATION OF HIF-1ALPHA$72,851
U54 · FY2007 · RR · contact PI
Center on Proteolytic Pathways(RMI)$3,960,022
U54 · FY2006 · RR · contact PI
Nanotherapy for Vulnerable Plaque$2,709,968
U01 · FY2006 · HL · contact PI
CORE 6 : PROJECT LEADERSHIP AND ADMINISTRATION$1,579,692
U54 · FY2006 · RR · contact PI
Core--Drug Screening and Chemistry Facility$715,022
P01 · FY2006 · AI · contact PI
Metalloproteinases in Tumor Progression and Metastasis$496,512
R01 · FY2006 · CA · contact PI
Vascular Integrins and Nitric Oxide$468,720
R01 · FY2006 · HL · contact PI
CORE 1 TRP2: PROTEASE ACTIVITY IMAGING TECHNOLOGY (PAIT)$364,005
U54 · FY2006 · RR · contact PI
A Variant of Ileal Bile Acid Binding Protein in Colon Cancer$160,400
R21 · FY2006 · CA · contact PI
CORE--Shared Resources Chemical Library$142,866
P30 · FY2006 · CA · contact PI
CORE 2 DB2: PROTEOLYTIC REGULATION OF HIF-1ALPHA$78,527
U54 · FY2006 · RR · contact PI
Center on Proteolytic Pathways(RMI)$3,553,090
U54 · FY2005 · RR
Nanotherapy for Vulnerable Plaque$1,472,216
U01 · FY2005 · HL
CORE 6 : PROJECT LEADERSHIP AND ADMINISTRATION$1,417,363
U54 · FY2005 · RR
Core--Drug Screening and Chemistry Facility$699,290
P01 · FY2005 · AI
Metalloproteinases in Tumor Progression and Metastasis$493,651
R01 · FY2005 · CA
Vascular Integrins and Nitric Oxide$480,000
R01 · FY2005 · HL
CORE 1 TRP2: PROTEASE ACTIVITY IMAGING TECHNOLOGY (PAIT)$326,600
U54 · FY2005 · RR
A Variant of Ileal Bile Acid Binding Protein in Colon Cancer$164,260
R21 · FY2005 · CA
CORE--Shared Resources Chemical Library$138,704
P30 · FY2005 · CA
CORE 2 DB2: PROTEOLYTIC REGULATION OF HIF-1ALPHA$70,458
U54 · FY2005 · RR
Center on Proteolytic Pathways (RMI)$3,725,956
U54 · FY2004 · RR
Core--Drug Screening and Chemistry Facility$784,774
P01 · FY2004 · AI
Vascular Integrins and Nitric Oxide$480,000
R01 · FY2004 · HL
CORE--Shared Resources Chemical Library$134,665
P30 · FY2004 · CA
Applied Biosystems QStar Pulsar I with oMALDI Source$488,108
S10 · FY2003 · RR
Vascular Integrins and Nitric Oxide$466,200
R01 · FY2003 · HL
DISINTEGRINS &METALLOPROTEINASES IN ORTHOPEDIC DISEASE$396,700
R01 · FY2002 · AR
ALPHA V INTEGRINS IN BREAST CANCER$321,116
R01 · FY2002 · CA
TARGETING THE ANGIOGENIC ADHESION CENTER$0
P01 · FY2002 · CA
Core--Biomolecular analysis$0
P30 · FY2002 · CA
TARGETING THE ANGIOGENIC ADHESION CENTER$0
P01 · FY2002 · CA
TARGETING THE ANGIOGENIC ADHESION CENTER$0
P01 · FY2002 · CA
TARGETING THE ANGIOGENIC ADHESION CENTER$0
P01 · FY2002 · CA
MECHANISM OF ACTIVATION OF PLATELET GPIIB AND GPIIIA$413,792
R01 · FY2001 · HL
DISINTEGRINS &METALLOPROTEINASES IN ORTHOPEDIC DISEASE$385,145
R01 · FY2001 · AR
ALPHA V INTEGRINS IN BREAST CANCER$311,762
R01 · FY2001 · CA
TARGETING THE ANGIOGENIC ADHESION CENTER$0
P01 · FY2001 · CA
Core--Biomolecular analysis$0
P30 · FY2001 · CA
MECHANISM OF ACTIVATION OF PLATELET GPIIB AND GPIIIA$401,741
R01 · FY2000 · HL
DISINTEGRINS &METALLOPROTEINASES IN ORTHOPEDIC DISEASE$373,928
R01 · FY2000 · AR
API 3000 ELECTROSPRAY MASS SPECTROMETER$371,354
S10 · FY2000 · RR
ALPHA V INTEGRINS IN BREAST CANCER$302,683
R01 · FY2000 · CA
Core--Biomolecular analysis$0
P30 · FY2000 · CA
TARGETING THE ANGIOGENIC ADHESION CENTER$0
P01 · FY2000 · CA